CoChat
Sign Up
Cited by 211Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes Management and Education

Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review

Open access
Okemah, Jennifer, Peng, John, Quiñones, Manuel·2018·Advances in Therapy
DOI 10.1007/s12325-018-0819-5PMC PMC6223992
Open this paper in CoChat — free accountOpen PDF

Abstract

The current epidemic of type 2 diabetes (T2D) represents a significant global and national health concern. Globally, the prevalence of diabetes has doubled between 1980 and 2014. In 2014 the World Health Organization estimated that there were 422 million adults living with diabetes worldwide. In the USA, the number of people diagnosed with T2D is estimated to increase to over 70 million by 2050, putting an immense strain on the US healthcare system. Achieving glycemic control is widely acknowledged as the key goal of treatment in T2D and is critical for reducing the onset and progression of diabetes-related complications such as cardiovascular diseases, neuropathies, retinopathies, and nephropathies. Despite the increase in the availability of antihyperglycemic medications and evidence-based treatment guidelines, the proportion of people with T2D who fail to achieve glycemic goals continues to rise. One major contributor is a delay in treatment intensification despite suboptimal glycemic control, referred to as clinical or therapeutic inertia. Clinical inertia prolongs the duration of patients' hyperglycemia which subsequently puts them at increased risk of diabetes-associated complications and reduced life expectancy. Clinical inertia results from a complex interaction between patient, healthcare providers, and healthcare system barriers that need to be addressed together, rather than as separate entities. In this article we provide an overview of clinical inertia in the clinical management of T2D and provide suggestions for overcoming aspects that may have a negative impact on patient care.Funding: Sanofi US, Inc.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12325-018-0819-5

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 53 · Cited by 211

Research works printed but not linked: 44

  1. [1]Carls G, Huynh J, Tuttle E, Yee J, Edelman SV. Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther. 2017;8(4):863–73. 28646411 10.1007/s13300-017-0280-5 PMC5544616 · DOI · Paper page
  2. [2]Stone MA, Charpentier G, Doggen K, et al. Quality of care of people with type 2 diabetes in eight European countries. Diabetes Care. 2013.36(9):2628–38. 23628621 10.2337/dc12-1759 PMC3747883 · DOI
  3. [3]Blonde L, Aschner P, Bailey C, et al. Gaps and barriers in the control of blood glucose in people with type 2 diabetes. Diab Vasc Dis Res. 2017;14(3):172–83. 28467203 10.1177/1479164116679775 PMC5418936 · DOI
  4. [4]O’Connor PJ. Improving diabetes care by combating clinical inertia. Health Serv Res. 2005;40(6 Pt 1):1854–61. 16336552 10.1111/j.1475-6773.2005.00437.x PMC1361230 · DOI
  5. [5]Ross SA. Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes. Am J Med. 2013;126(9 Suppl 1):S38–48. 23953078 10.1016/j.amjmed.2013.06.012 · DOI
  6. [6]Aujoulat I, Jacquemin P, Rietzschel E, et al. Factors associated with clinical inertia: an integrative review. Adv Med Educ Pract. 2014;5:141–7. 24868181 10.2147/AMEP.S59022 PMC4028485 · DOI
  7. [7]Khunti S, Davies MJ, Khunti K. Clinical inertia in the management of type 2 diabetes mellitus: a focused literature review. Br J Diabetes Vasc Dis. 2015;15:65–9. 10.15277/bjdvd.2015.019 · DOI
  8. [8]Khunti K, Millar-Jones D. Clinical inertia to insulin initiation and intensification in the UK: a focused literature review. Prim Care Diabetes. 2017;11(1):3–12. 27727005 10.1016/j.pcd.2016.09.003 · DOI
  9. [9]Khunti K, Gomes MB, Pocock S, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab. 2018;20(2):427–37. 28834075 10.1111/dom.13088 PMC5813232 · DOI
  10. [11]Goodall G, Sarpong EM, Hayes C, Valentine WJ. The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocr Disord. 2009;9:19. 19804622 10.1186/1472-6823-9-19 PMC2761913 · DOI
  11. [12]Arnold LW, Wang Z. The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies. Rev Diabet Stud. 2014;11(2):138–52. 25396402 10.1900/RDS.2014.11.138 PMC4310064 · DOI
  12. [13]Paprott R, Schaffrath Rosario A, Busch MA, et al. Association between hemoglobin A 1c and all-cause mortality: results of the mortality follow-up of the German National Health Interview and Examination Survey 1998. Diabetes Care. 2015;38:249–56. 25414153 10.2337/dc14-1787 · DOI
  13. [14]Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100. 26249018 10.1186/s12933-015-0260-x PMC4528846 · DOI
  14. [15]Strain WD, Blüher M, Paldánius P. Clinical inertia in individualising care for diabetes: is there time to do more in type 2 diabetes? Diabetes Ther. 2014;5(2):347–54. 25113408 10.1007/s13300-014-0077-8 PMC4269638 · DOI
  15. [18]Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18(4):401–9. 26743666 10.1111/dom.12626 PMC5067688 · DOI · Paper page
  16. [19]Pantalone KM, Misra-Hebert AD, Hobbs TM, et al. Clinical inertia in type 2 diabetes management: evidence from a large, real-world data set. Diabetes Care. 2018;41:e113–4. 29678811 10.2337/dc18-0116 · DOI
  17. [20]Blonde L, Meneghini L, Peng XV, et al. Probability of achieving glycemic control with basal insulin in patients with type 2 diabetes in real-world practice in the USA. Diabetes Ther. 2018;9(3):1347–58. 29600507 10.1007/s13300-018-0413-5 PMC5984916 · DOI
  18. [22]Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin. 2011;27(Suppl 3):13–20. 10.1185/03007995.2011.621416 21942467 · DOI
  19. [25]Zafar A, Stone MA, Davies MJ, Khunti K. Acknowledging and allocating responsibility for clinical inertia in the management of type 2 diabetes in primary care: a qualitative study. Diabet Med. 2015;32(3):407–13. 25251768 10.1111/dme.12592 · DOI · Paper page
  20. [26]Phillips LS, Barb D, Yong C, et al. Translating what works: a new approach to improve diabetes management. J Diabetes Sci Technol. 2015;9(4):857–64. 25759182 10.1177/1932296815576000 PMC4525659 · DOI
  21. [27]Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43(6):501–11. 28754263 10.1016/j.diabet.2017.06.003 · DOI
  22. [28]Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care. 2005;28(11):2673–9. 16249538 10.2337/diacare.28.11.2673 · DOI
  23. [29]Berard L, Bonnemaire M, Mical M, Edelman S. Insights into optimal basal insulin titration in type 2 diabetes: results of a quantitative survey. Diabetes Obes Metab. 2018;20(2):301–8. 28719066 10.1111/dom.13064 PMC5811840 · DOI · Paper page
  24. [30]American Association of Clinical Endocrinologists (AACE). Surveys find adults with type 2 diabetes are more willing to take action to achieve A1c targets quicker than physicians and other medical professionals perceive. AACE Online Newsroom. http://media.aace.com/press-release/surveys-find-adults-type-2-diabetes-are-more-willing-take-action-achieve-a1c-targets-q. Accessed 29 June 2018.
  25. [31]Nakar S, Yitzhaki G, Rosenberg R, Vinker S. Transition to insulin in type 2 diabetes: family physicians’ misconception of patients’ fears contributes to existing barriers. J Diabetes Complications. 2007;21(4):220–6. 17616351 10.1016/j.jdiacomp.2006.02.004 · DOI
  26. [32]Yoshioka N, Ishii H, Tajima N, Iwamoto Y, DAWN Japan group. Differences in physician and patient perceptions about insulin therapy for management of type 2 diabetes: the DAWN Japan study. Curr Med Res Opin. 2014;30(2):177–83. 24128339
  27. [33]Saeed H, Saleem Z, Naeem I, Shahzadi I, Islam M. Impact of health literacy on diabetes outcomes: a cross-sectional study from Lahore, Pakistan. Public Health. 2018;156:8–14. 29353668 10.1016/j.puhe.2017.12.005 · DOI
  28. [34]Schillinger D, Grumbach K, Piette J, et al. Association of health literacy with diabetes outcomes. JAMA. 2002;288(4):475–82. 12132978 10.1001/jama.288.4.475 · DOI
  29. [35]Souza JG, Apolinario D, Magaldi RM, Leopold Busse A, Campora F, Jacob-Flinto W. Functional health literacy and glycemic control in older adults with type 2 diabetes: a cross-sectional study. BMJ Open. 2014;4:e004180. 10.1136/bmjopen-2013-004180 PMC3927799 24525392 · DOI
  30. [37]McBrien KA, Naugler C, Ivers N, et al. Barriers to care in patients with diabetes and poor glycemic control-A cross-sectional survey. PLoS One. 2017;12(5):e0176135. 28459820 10.1371/journal.pone.0176135 PMC5411045 · DOI
  31. [39]Vencio S, Paldánius PM, Blüher M, Giannella-Neto D, Caiado-Vencio R, Strain WD. Understanding the barriers and improving care in type 2 diabetes: Brazilian perspective in time to do more in diabetes. Diabetol Metab Syndr. 2017;9:46. 28638444 10.1186/s13098-017-0244-y PMC5472944 · DOI
  32. [41]Serrano V, Rodriguez-Gutierrez R, Hargraves I, Gionfriddo MR, Tamhane S, Montori VM. Shared decision-making in the care of individuals with diabetes. Diabet Med. 2016;33(6):742–51. 27105298 10.1111/dme.13143 · DOI
  33. [42]Reach G, Le Pautremat V, Gupta S. Determinants and consequences of insulin initiation for type 2 diabetes in France: analysis of the National Health and Wellness Survey. Patient Prefer Adherence. 2013;7:1007–23. 24143079 10.2147/PPA.S51299 PMC3797252 · DOI
  34. [43]Eriksen J, Gustafsson LL, Ateva K, et al. High adherence to the ‘Wise List’ treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines. BMJ Open. 2017;7:e014345. 10.1136/bmjopen-2016-014345 PMC5775463 28465306 · DOI
  35. [44]Salisbury C, Fahey T. Overcoming clinical inertia in the management of hypertension. CMAJ. 2006;174(9):1285–6. 16636328 10.1503/cmaj.060243 PMC1435955 · DOI
  36. [45]van Bruggen R, Gorter K, Stolk R, Klungel O, Rutten G. Clinical inertia in general practice: widespread and related to the outcome of diabetes care. Fam Pract. 2009;26(6):428–36. 19729401 10.1093/fampra/cmp053 · DOI
  37. [46]Laursen DH, Christensen KB, Christensen U, Frølich A. Assessment of short and long-term outcomes of diabetes patient education using the health education impact questionnaire (HeiQ). BMC Res Notes. 2017;10(1):213. 28619041 10.1186/s13104-017-2536-6 PMC5471707 · DOI
  38. [47]Powers MA, Bardsley J, Cypress M. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Clin Diabetes. 2016;34(2):70–80. 27092016 10.2337/diaclin.34.2.70 PMC4833481 · DOI · Paper page
  39. [48]Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2017 Executive Summary. Endocrine Practice. 2018;24(1):91–120. 29368965 10.4158/CS-2017-0153 · DOI
  40. [49]Li J, Gong Y, Li C, Lu Y, Liu Y, Shao Y. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: a meta-analysis. Medicine (Baltimore). 2017;96(27):e7201. 28682870 10.1097/MD.0000000000007201 PMC5502143 · DOI
  41. [50]Baker WL, Buckley LF, Kelly MS, et al. Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6(5):e005686. PMC5524106 28522675
  42. [51]Valentine V, Goldman J, Shubrook JH. Rationale for, initiation and titration of the basal insulin/GLP-1RA fixed-ratio combination products, IDegLira and IGlarLixi, for the management of type 2 diabetes. Diabetes Ther. 2017;8(4):739–52. 28721686 10.1007/s13300-017-0287-y PMC5544623 · DOI
  43. [52]Rosenstock J, Guerci B, Hanefeld M, et al. Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal Duo-2 trial. Diabetes Care. 2016;39(8):1318–28. 27222510 10.2337/dc16-0014 · DOI
  44. [53]Kaneko S, Chow F, Choi DS, et al. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial. Diabetes Res Clin Pract. 2015;107(1):139–47. 25498130 10.1016/j.diabres.2014.09.026 · DOI

Authors
Okemah, J., Peng, J., & Quiñones, M.
Affiliations
Virginia Mason Lynnwood Medical Center (US)
Corresponding author
Okemah, Jennifer
ORCID
Okemah, Jennifer
Venue
Advances in Therapy
Publisher
Springer Science and Business Media LLC
Published
2018-10-29
Volume
35
Issue
11
Pages
1735-1745
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
DOI
10.1007/s12325-018-0819-5
PMC
PMC6223992
OpenAlex
W2899009485
Cited by
211
References
53
Citations by year
2026: 13 · 2025: 29 · 2024: 23 · 2023: 33 · 2022: 21 · 2021: 47 · 2020: 31 · 2019: 14
FWCI
3.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Advances in Therapy (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Sanofi US, Inc.
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
type 2 diabetes, clinical inertia, therapeutic inertia, glycemic control, treatment intensification, antihyperglycemic medications, diabetes complications, barriers to care, patient care
MeSH terms
Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Female, Humans, Hyperglycemia, Hypoglycemic Agents, Male, Middle Aged, United States, Practice Guidelines as Topic, Early Diagnosis, Time-to-Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review